Does Manual Lymphatic Drainage Add Value in Reducing Suprafascial Fluid Accumulation and Skin Elasticity in Patients With Breast Cancer-Related Lymphedema?


Journal

Physical therapy
ISSN: 1538-6724
Titre abrégé: Phys Ther
Pays: United States
ID NLM: 0022623

Informations de publication

Date de publication:
06 12 2022
Historique:
received: 22 09 2021
revised: 31 03 2022
accepted: 10 07 2022
medline: 4 9 2023
pubmed: 10 10 2022
entrez: 9 10 2022
Statut: ppublish

Résumé

The purpose of this study was to investigate the effectiveness of fluoroscopy-guided manual lymph drainage (MLD) versus that of traditional and placebo MLD, when added to decongestive lymphatic therapy (DLT) for the treatment of breast cancer-related lymphedema (BCRL) (EFforT-BCRL trial), on the suprafascial accumulation of lymphatic fluid and skin elasticity. In this multicenter, 3-arm, double-blind, randomized controlled trial (EFforT-BCRL trial), 194 participants (mean age = 61 [SD = 10] years) with unilateral BCRL were recruited. All participants received standardized DLT (education, skin care, compression therapy, exercises) and were randomized to fluoroscopy-guided, traditional, or placebo MLD. Participants received 60 min/d of treatment during the 3-week intensive phase and 18 sessions of 30 minutes during the 6-month maintenance phase. During this phase, participants were instructed to wear a compression garment, to perform exercises, and to perform a self-MLD procedure once daily. This study comprises secondary analyses of the EFforT-BCRL trial. Outcomes were the amount of fluid accumulation in the suprafascial tissues (local tissue water, extracellular fluid, and thickness of the skin and subcutaneous tissue) and skin elasticity at the level of the arm and trunk. Measurements were performed at baseline; after intensive treatment; after 1, 3, and 6 months of maintenance treatment; and after 6 months of follow-up. At the level of the arm, there was a significant improvement over time in the 3 groups for most of the outcomes. At the level of the trunk, no remarkable improvement was noted within the individual groups. No significant interaction effects (between-group differences) were present. Only skin elasticity at the level of the arm, evaluated through palpation, showed a significant interaction effect. All 3 groups showed similar improvements in response to DLT regardless of the type of MLD that was added. The effect of the addition of MLD to other components of DLT for reducing local tissue water and extracellular fluid or skin thickness and for improving skin elasticity and fibrosis in participants with chronic BCRL was limited. Although MLD has been applied all over the world for many years, evidence regarding its added value in reducing arm volume in patients with BCRL is lacking. These results show that adding MLD to other components of DLT has limited value in reducing local tissue water and extracellular fluid or skin thickness and in improving skin elasticity and fibrosis in patients with chronic BCRL. To date, there is no clinical indication to continue including time-consuming MLD in physical therapist sessions for patients with chronic BCRL.

Identifiants

pubmed: 36209432
pii: 6754370
doi: 10.1093/ptj/pzac137
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02609724']
EudraCT
['2015–004822-33']

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2022 American Physical Therapy Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Tessa De Vrieze (T)

KU Leuven - University of Leuven, Department of Rehabilitation Sciences, Leuven, Belgium.
University of Antwerp, Department of Rehabilitation Sciences and Physiotherapy, MOVANT, Antwerp, Belgium.

Nick Gebruers (N)

University of Antwerp, Department of Rehabilitation Sciences and Physiotherapy, MOVANT, Antwerp, Belgium.
University of Antwerp and Antwerp University Hospital, Multidisciplinary Oedema Clinic, Antwerp, Belgium.

Ines Nevelsteen (I)

UZ Leuven - University Hospitals Leuven, Multidisciplinary Breast Centre, Leuven, Belgium.

Sarah Thomis (S)

UZ Leuven - University Hospitals Leuven, Department of Vascular Surgery and Department of Physical Medicine and Rehabilitation, Centre for Lymphoedema, Leuven, Belgium.

An De Groef (A)

KU Leuven - University of Leuven, Department of Rehabilitation Sciences, Leuven, Belgium.
University of Antwerp, Department of Rehabilitation Sciences and Physiotherapy, MOVANT, Antwerp, Belgium.

Wiebren A A Tjalma (WAA)

University of Antwerp and Antwerp University Hospital, Multidisciplinary Oedema Clinic, Antwerp, Belgium.
University of Antwerp, Department of Medicine, MIPRO, Antwerp, Belgium.
Antwerp University Hospital, Multidisciplinary Breast Clinic, Antwerp, Belgium.

Jean-Paul Belgrado (JP)

Université Libre de Bruxelles, Lymphology Research Unit, Brussels, Belgium.

Liesbeth Vandermeeren (L)

Mirha Multidisciplinary Clinic, Zaventem, Belgium.

Chris Monten (C)

Ghent University Hospital, Department of Radiotherapy, Ghent, Belgium.

Marianne Hanssens (M)

General Hospital Groeninge, Department of Oncology, Centre for Oncology, Kortrijk, Belgium.

Anne Asnong (A)

KU Leuven - University of Leuven, Department of Rehabilitation Sciences, Leuven, Belgium.

Lore Dams (L)

University of Antwerp, Department of Rehabilitation Sciences and Physiotherapy, MOVANT, Antwerp, Belgium.

Elien Van der Gucht (E)

KU Leuven - University of Leuven, Department of Rehabilitation Sciences, Leuven, Belgium.

An-Kathleen Heroes (AK)

KU Leuven - University of Leuven, Department of Rehabilitation Sciences, Leuven, Belgium.

Nele Devoogdt (N)

KU Leuven - University of Leuven, Department of Rehabilitation Sciences, Leuven, Belgium.
UZ Leuven - University Hospitals Leuven, Department of Vascular Surgery and Department of Physical Medicine and Rehabilitation, Centre for Lymphoedema, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH